194 related articles for article (PubMed ID: 10931444)
1. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues.
Chen J; Falla TJ; Liu H; Hurst MA; Fujii CA; Mosca DA; Embree JR; Loury DJ; Radel PA; Cheng Chang C; Gu L; Fiddes JC
Biopolymers; 2000; 55(1):88-98. PubMed ID: 10931444
[TBL] [Abstract][Full Text] [Related]
2. Intramolecular disulfide bonds enhance the antimicrobial and lytic activities of protegrins at physiological sodium chloride concentrations.
Harwig SS; Waring A; Yang HJ; Cho Y; Tan L; Lehrer RI
Eur J Biochem; 1996 Sep; 240(2):352-7. PubMed ID: 8841398
[TBL] [Abstract][Full Text] [Related]
3. Membranolytic selectivity of cystine-stabilized cyclic protegrins.
Tam JP; Wu C; Yang JL
Eur J Biochem; 2000 Jun; 267(11):3289-300. PubMed ID: 10824115
[TBL] [Abstract][Full Text] [Related]
4. Killing of Fusobacterium nucleatum, Porphyromonas gingivalis and Prevotella intermedia by protegrins.
Miyasaki KT; Iofel R; Oren A; Huynh T; Lehrer RI
J Periodontal Res; 1998 Feb; 33(2):91-8. PubMed ID: 9553868
[TBL] [Abstract][Full Text] [Related]
5. Design of non-cysteine-containing antimicrobial beta-hairpins: structure-activity relationship studies with linear protegrin-1 analogues.
Lai JR; Huck BR; Weisblum B; Gellman SH
Biochemistry; 2002 Oct; 41(42):12835-42. PubMed ID: 12379126
[TBL] [Abstract][Full Text] [Related]
6. Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I.
Robinson JA; Shankaramma SC; Jetter P; Kienzl U; Schwendener RA; Vrijbloed JW; Obrecht D
Bioorg Med Chem; 2005 Mar; 13(6):2055-64. PubMed ID: 15727859
[TBL] [Abstract][Full Text] [Related]
7. IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis.
Mosca DA; Hurst MA; So W; Viajar BS; Fujii CA; Falla TJ
Antimicrob Agents Chemother; 2000 Jul; 44(7):1803-8. PubMed ID: 10858334
[TBL] [Abstract][Full Text] [Related]
8. Beta-sheet antibiotic peptides as potential dental therapeutics.
Miyasaki KT; Lehrer RI
Int J Antimicrob Agents; 1998 Feb; 9(4):269-80. PubMed ID: 9573496
[TBL] [Abstract][Full Text] [Related]
9. Using fluorous amino acids to probe the effects of changing hydrophobicity on the physical and biological properties of the beta-hairpin antimicrobial peptide protegrin-1.
Gottler LM; de la Salud Bea R; Shelburne CE; Ramamoorthy A; Marsh EN
Biochemistry; 2008 Sep; 47(35):9243-50. PubMed ID: 18693751
[TBL] [Abstract][Full Text] [Related]
10. Solution structure of protegrin-1, a broad-spectrum antimicrobial peptide from porcine leukocytes.
Fahrner RL; Dieckmann T; Harwig SS; Lehrer RI; Eisenberg D; Feigon J
Chem Biol; 1996 Jul; 3(7):543-50. PubMed ID: 8807886
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Evaluation of Amphiphilic Cyclic and Linear Peptides Composed of Hydrophobic and Positively-Charged Amino Acids as Antibacterial Agents.
Riahifard N; Mozaffari S; Aldakhil T; Nunez F; Alshammari Q; Alshammari S; Yamaki J; Parang K; Tiwari RK
Molecules; 2018 Oct; 23(10):. PubMed ID: 30360400
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and solution structure of the antimicrobial peptide protegrin-1.
Aumelas A; Mangoni M; Roumestand C; Chiche L; Despaux E; Grassy G; Calas B; Chavanieu A
Eur J Biochem; 1996 May; 237(3):575-83. PubMed ID: 8647100
[TBL] [Abstract][Full Text] [Related]
13. QSAR analysis of antimicrobial and haemolytic effects of cyclic cationic antimicrobial peptides derived from protegrin-1.
Frecer V
Bioorg Med Chem; 2006 Sep; 14(17):6065-74. PubMed ID: 16714114
[TBL] [Abstract][Full Text] [Related]
14. Protegrin antimicrobial peptides.
Fiddes JC
Curr Opin Drug Discov Devel; 2000 Sep; 3(5):655. PubMed ID: 19649894
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
Gobbo M; Biondi L; Filira F; Gennaro R; Benincasa M; Scolaro B; Rocchi R
J Med Chem; 2002 Sep; 45(20):4494-504. PubMed ID: 12238928
[TBL] [Abstract][Full Text] [Related]
16. Structural and biological evaluation of some loloatin C analogues.
Tuin AW; Grotenbreg GM; Spalburg E; de Neeling AJ; Mars-Groenendijk RH; van der Marel GA; Noort D; Overkleeft HS; Overhand M
Bioorg Med Chem; 2009 Sep; 17(17):6233-40. PubMed ID: 19679485
[TBL] [Abstract][Full Text] [Related]
17. Protegrins: structural requirements for inactivating elementary bodies of Chlamydia trachomatis.
Yasin B; Lehrer RI; Harwig SS; Wagar EA
Infect Immun; 1996 Nov; 64(11):4863-6. PubMed ID: 8890254
[TBL] [Abstract][Full Text] [Related]
18. Endogenous vertebrate antibiotics. Defensins, protegrins, and other cysteine-rich antimicrobial peptides.
Lehrer RI; Ganz T
Ann N Y Acad Sci; 1996 Oct; 797():228-39. PubMed ID: 8993365
[TBL] [Abstract][Full Text] [Related]
19. Protegrin structure-activity relationships: using homology models of synthetic sequences to determine structural characteristics important for activity.
Ostberg N; Kaznessis Y
Peptides; 2005 Feb; 26(2):197-206. PubMed ID: 15629531
[TBL] [Abstract][Full Text] [Related]
20. Cysteine deleted protegrin-1 (CDP-1): anti-bacterial activity, outer-membrane disruption and selectivity.
Mohanram H; Bhattacharjya S
Biochim Biophys Acta; 2014 Oct; 1840(10):3006-16. PubMed ID: 24997421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
